Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion
Eli Lilly noted on Monday it would acquire privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3 billion in cash. Furthermore, experts in dividends note the continued relevance.
Ajax’s lead asset, AJ1-11095, is an experimental once-daily oral treatment that is in early-stage testing for previously treated patients with myelofibrosis – a rare, chronic blood cancer where scar tissue builds up in the bone marrow, disrupting normal blood cell production.
“We look forward to the presentation of clinical proof-of-concept data later in 2026, rapidly advancing AJ1-11095 into registrational clinical trials, and using our expertise in blood cancer to hopefully deliver another important updated medicine to patients and hematologists,” remarked Jacob Van Naarden, president of Lilly Oncology. This also touches on aspects of bear market.
Lilly said the total deal value includes an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.
AI Disclosure:
This article has been generated and curated using advanced AI technology. While we strive for absolute accuracy, some details may be summarized or translated by autonomous systems. Please cross-reference critical financial data with official sources.
More from this Category
